Ambrisentan
- Generic Name
- Ambrisentan
- Brand Names
- Letairis, Volibris, Ambrisentan Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H22N2O4
- CAS Number
- 177036-94-1
- Unique Ingredient Identifier
- HW6NV07QEC
- Background
Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with ...
- Indication
用于治疗肺动脉高血压(PAH)。
- Associated Conditions
- Pulmonary arterial hypertension WHO functional class I
- Associated Therapies
- -
Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)
- Conditions
- Interventions
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Heidelberg University
- Target Recruit Count
- 38
- Registration Number
- NCT02290613
- Locations
- 🇩🇪
Thoraxclinic at the University of Heidelberg, Heidelberg, Germany
Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- National Jewish Health
- Target Recruit Count
- 7
- Registration Number
- NCT02169752
- Locations
- 🇺🇸
National Jewish Health, Denver, Colorado, United States
Ambrisentan in Single Ventricle
- Conditions
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Kevin Hill
- Target Recruit Count
- 16
- Registration Number
- NCT02080637
- Locations
- 🇺🇸
Duke Universtiy Hospital, Durham, North Carolina, United States
The Effects of Ambrisentan on Exercise Capacity in Fontan Patients
- First Posted Date
- 2013-10-29
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 28
- Registration Number
- NCT01971580
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 134
- Registration Number
- NCT01808313
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Ambrisentan for Treatment of Portopulmonary Hypertension
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Medical University of Graz
- Registration Number
- NCT01733095
- Locations
- 🇦🇹
Medical University of Graz, Graz, Austria
Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2012-06-12
- Lead Sponsor
- University of Glasgow
- Target Recruit Count
- 18
- Registration Number
- NCT01617746
- Locations
- 🇬🇧
Asthma Research Unit, University of Glasgow, Glasgow, United Kingdom
The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2014-01-16
- Lead Sponsor
- Thies Schroeder
- Target Recruit Count
- 18
- Registration Number
- NCT01530464
- Locations
- 🇺🇸
Duke Clinical Research Unit, Durham, North Carolina, United States
Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 900
- Registration Number
- NCT01406327
Characterization and Detection of Prolonged Endothelin Receptors Antagonists Administration
- Conditions
- Interventions
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2013-05-08
- Target Recruit Count
- 30
- Registration Number
- NCT01352065
- Locations
- 🇷🇸
Center for Health, Exercise and Sport Sciences, Belgrade, Serbia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.